Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
Reported Saturday, Merck And Eisai's Phase 3 LEAP-012 Trial OF KEYTRUDA-LENVIMA Combo Shows 34% Reduction In Progression For Advanced Liver Cancer
報道稱，默沙東和愛文思控股的第3階段LEAP-012試驗顯示，Keytruda-Lenvima組合在愛文思控股肝癌晚期患者中顯示出34%的療效提升。
- In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone
- Late-breaking first interim analysis results are being presented during a Presidential Symposium session at the European Society for Medical Oncology Congress 2024
- 在 LEAP-012 第 3 期試驗中，與單獨的 TACE 相比，KEYTRUDA 和 LENVIMA 與 TACE 聯合使用可將疾病進展或死亡的風險降低了 34%
- 最新的首次中期分析結果將在2024年歐洲腫瘤內科學會大會的總統研討會上公佈